Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial

Histone Deacetylase Inhibitors: Design, Structure-Activity Relationships and Therapeutic Implications for Cancer

(2012) Charles Marson   Anti-Cancer Agents in Medicinal Chemistry

Development of vorinostat: Current applications and future perspectives for cancer therapy

(2009) Victoria M. Richon et al.   CANCER LETTERS

Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors

(2009) Yutaka Fujiwara et al.   CANCER SCIENCE

Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids

(2009) Valérie Lobjois et al.   EUROPEAN JOURNAL OF CANCER

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

(2009) Evanthia Galanis et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics and pharmacogenomics in gastric cancer chemotherapy

(2008) Masahiko Nishiyama et al.   ADVANCED DRUG DELIVERY REVIEWS

Role of transforming growth factor-β superfamily signaling pathways in human disease

(2008) Kelly J. Gordon et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study

(2008) T. H. Luu et al.   CLINICAL CANCER RESEARCH

DNA Hypermethylation Contributes to Incomplete Synthesis of Carbohydrate Determinants in Gastrointestinal Cancer

(2008) Yuki I. Kawamura et al.   GASTROENTEROLOGY

Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma

(2008) Jennifer A. Woyach et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM